Can the AHCL System Be Used in T1D Patients with Borderline TDDI? A Case Report
Abstract
:1. Introduction
2. Materials and Methods
This Work Was Based on the Medtronic Systems
3. Case Report
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Collyns, O.J.; Meier, R.A.; Betts, Z.L.; Chan, D.S.; Frampton, C.; Frewen, C.M.; Hewapathirana, N.M.; Jones, S.D.; Roy, A.; Grosman, B.; et al. Improved glycemic outcomes with medtronic minimed advanced hybrid closed-loop delivery: Results from a randomized crossover trial comparing automated insulin delivery with predictive low glucose suspend in peoplewithtype1diabetes. Diabetes Care 2021, 44, 969–975. [Google Scholar] [CrossRef] [PubMed]
- Petrovski, G.; Al Khalaf, F.; Campbell, J.; Fisher, H.; Umer, F.; Hussain, K. 10-Day structured initiation protocol from multiple daily injection to hybrid closed-loop system in children and adolescents with type 1 diabetes. Acta Diabetol. 2020, 57, 681–687. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kordonouri, O.; Hartmann, R.; Pańkowska, E.; Rami-Merhar, B.; Kapellen, T.; Coutant, R.; Lange, K.; Danne, T. Sensor augmented pump therapy from onset of type 1 diabetes: Late follow-up results of the Pediatric Onset Study. Pediatr. Diabetes 2012, 13, 515–518. [Google Scholar] [CrossRef] [PubMed]
- Bergenstal, R.M.; Nimri, R.; Beck, R.W.; Criego, A.; Laffel, L.; Schatz, D.; Battelino, T.; Danne, T.; A Weinzimer, S.; Sibayan, J.; et al. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): A multicentre, randomised, crossover trial. Lancet 2021, 397, 208–219. [Google Scholar] [CrossRef]
- Medtronic MiniMed. Minimed® 670G System User Guide. 2017. Available online: https://www.medtronicdiabetes.com/sites/default/files/library/download-library/user-guides/MiniMed-670G-System-User-Guide.pdf (accessed on 11 June 2021).
- MiniMed™ 780G System with Guardian™ 4 Sensor. Available online: https://www.medtronic-diabetes.co.uk/insulin-pump-therapy/minimed-780g-system (accessed on 11 June 2021).
- Insulet Corporation: Omnipod® 5 Clinical Results. Available online: https://investor.insulet.com/static-files/8969ea97-a10d-4d81-92c5-eca3e17f2f44 (accessed on 27 October 2021).
- See How Easy Control Can Be The t:slim X2 pump with Control-IQ Technology Predicts and Helps Prevent Highs and Lows. Available online: https://www.tandemdiabetes.com/products/t-slim-x2-insulin-pump/control-iq (accessed on 11 June 2021).
- Medtronic User Guide Minimed 780G. Available online: https://www.medtronic-diabetes.co.uk/sites/uk/medtronic-diabetes.co.uk/files/pdf/m003192c021doc_a_final_web_mm780g_ifu_mmol_compressed.pdf (accessed on 11 June 2021).
- Medtronic Secures CE Mark for MiniMed™ 780G Advanced Hybrid Closed Loop System Designed to Further Simplify Type 1 Diabetes Management. Available online: https://news.medtronic.com/2020-06-11-Medtronic-Secures-CE-Mark-for-MiniMed-TM-780G-Advanced-Hybrid-Closed-Loop-System-Designed-to-Further-Simplify-Type-1-Diabetes-Management (accessed on 11 June 2021).
- Study Compares MiniMed 780G and MiniMed 670G Algorithms. Available online: https://diatribe.org/study-compares-minimed-780g-and-minimed-670g-algorithms (accessed on 11 June 2021).
- Jamiołkowska-sztabkowska, M.; Głowińska-olszewska, B.; Bossowski, A. C-peptide and residual β -cell function in pediatric diabetes–state of the art C-peptyd i resztkowa funkcja komórek β trzustki w cukrzycy u dzieci–aktualny stan wiedzy. Pediatr. Endocrinol. Diabetes Metab. 2021, 27, 123–133. [Google Scholar] [CrossRef] [PubMed]
- MiniMed TM 640G User Manual. Available online: https://www.medtronic-diabetes.co.uk/sites/uk/medtronic-diabetes.co.uk/files/pdf/minimed_640g_-_system_user_guide.pdf (accessed on 20 May 2021).
- SmartGuard™ Auto Mode. Available online: https://www.medtronic-diabetes.co.uk/insulin-pump-therapy/minimed-670g-system/smartguard-automode (accessed on 20 May 2021).
- Wolfsdorf, J.I.; Glaser, N.; Agus, M.; Fritsch, M.; Hanas, R.; Rewers, A.; Sperling, M.A.; Codner, E. ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic ketoacidosis and the hyperglycemic hyperosmolar state. Pediatr. Diabetes 2018, 19, 155–177. [Google Scholar] [CrossRef] [PubMed]
- Couper, J.J.; Haller, M.J.; Greenbaum, C.J.; Ziegler, A.-G.; Wherrett, D.K.; Knip, M.; Craig, M.E. ISPAD Clinical Practice Consensus Guidelines 2018: Stages of type 1 diabetes in children and adolescents. Pediatr. Diabetes 2018, 19, 20–27. [Google Scholar] [CrossRef] [PubMed]
- Co Diabetyk ma Refundowane w 2020 roku? 21 01 2020, Lek. Aleksandra Maciążka-Malec. Available online: https://diabetyk24.pl/blog-section/co-diabetyk-ma-refundowane-w-2020 (accessed on 20 May 2021).
- A Healthy Lifestyle. Available online: https://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle (accessed on 20 May 2021).
- Smart, C.E.; Annan, F.; Higgins, L.A.; Jelleryd, E.; Lopez, M.; Acerini, C.L. ISPAD Clinical Practice Consensus Guidelines 2018: Nutritional management in children and adolescents with diabetes. Pediatr. Diabetes 2018, 19, 136–154. [Google Scholar] [CrossRef] [PubMed]
- Araszkiewicz, A.; Bandurska-Stankiewicz, E.; Borys, S.; Budzyński, A.; Cyganek, K.; Cypryk, K.; Czech, A.; Czupryniak, L.; Drzewoski, J.; Dzida, G.; et al. 2021 Guidelines on the management of patients with diabetes. A position of Diabetes Poland. Clin. Diabetol. 2021, 10, 1–113. [Google Scholar] [CrossRef]
- Ludvigsson, J.; Heding, L.G. C-peptide in juvenile diabetes. Acta Paediatr. Scand. Suppl. 1977, 66, 53–62. [Google Scholar] [CrossRef] [PubMed]
- Steffes, M.W.; Sibley, S.; Jackson, M.; Thomas, W. Beta-Cell Function and the Development of Diabetes-Related Complications in the Diabetes Control Complications Trial. Diabetes Care 2003, 26, 832–836. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann. Intern. Med. 1998, 128, 517–523. [Google Scholar] [CrossRef] [PubMed]
- Buckingham, B.; Beck, R.W.; Ruedy, K.J.; Cheng, P.; Kollman, C.; Weinzimer, S.A.; DiMeglio, L.; Bremer, A.A.; Slover, R.; Tamborlane, W.V.; et al. Effectiveness of early intensive therapy onb-cell preservation in type 1 diabetes. Diabetes Care 2013, 36, 4030–4035. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nimri, R.; Grosman, B.; Roy, A.; Nir, J.; Shvalb, N.F.; Kurtz, N.; Loewenthal, N.; Gillon-Keren, M.; Muller, I.; Atlas, E.; et al. Feasibility Study of a Hybrid Closed-Loop System with Automated Insulin Correction Boluses. Diabetes Technol. Ther. 2021, 23, 268–276. [Google Scholar] [CrossRef] [PubMed]
- Pozzilli, P.; Manfrini, S.; Buzzetti, R.; Lampeter, E.; Leeuw, I.; Iafusco, D.; Prisco, M.; Ionescu-Tirgoviste, C.; Kolouskovà, S.; Linn, T.; et al. Glucose evaluation trial for remission (GETREM) in type 1 diabetes: A European multicentre study. Diabetes Res. Clin. Pract. 2005, 68, 258–264. [Google Scholar] [CrossRef] [PubMed]
Visit | Date of Visit | Body Weight | Height | Body Mass Index (BMI) | Total Daily Dose of Insulin (TDDI) | Daily Insulin Requirement/kg Body Weight | Glycated Hemoglobin (HbA1c) | |||
---|---|---|---|---|---|---|---|---|---|---|
(kg) | (pc) | (cm) | (pc) | (kg/m2) | (pc) | (units) | (units/1 kg bw) | (%) | ||
1 | 02 November 2020 | 50.90 | 96 | 147.5 | 93 | 23.60 | 95 | 22.70 | 0.45 | 12.20 |
2 | 16 November 2020 | 50.90 | 96 | 147.5 | 93 | 23.60 | 95 | 20.02 | 0.40 | 5.90 |
3 | 17 December 2020 | 49.00 | 95 | 150.00 | 95 | 21.80 | 91 | 12.50 | 0.26 | 5.90 |
4 | 19 February 2021 | 44.70 | 89 | 151.50 | 96 | 19.50 | 79 | 8.50 | 0.18 | 5.90 |
5 | 18 March 2021 | 43.40 | 86 | 151.50 | 96 | 18.90 | 74 | 8.20 | 0.20 | 6.10 |
Medtronic CGM Metrics | |||||||
---|---|---|---|---|---|---|---|
Type of System | MiniMed 640G | Minimed 780G | |||||
(Last 15 Days of Use) | Manual Mode (1 Week) | Automatic Mode (2 Weeks × 4) | |||||
Period | 3 February 2021–17 February 2021 | 20 February 2021–26 February 2021 | 27 February 2021–12 March 2021 | 13 March 2021–26 March 2021 | 27 March 2021–9 April 2021 | 10 April 2021–23 April 2021 | |
Pump read | 1 | 2 | 3 | 4 | 5 | 6 | |
Mean glucose concentration from sensor (mg/dL ± SD) | 110.00 ± 26 | 113.00 ± 23 | 118.00 ± 25 | 121.00 ± 26 | 119.00 ± 24 | 129.00 ± 29 | |
Glucose management indicator (GMI) (%) | 5.94 | 6.01 | 6.13 | 6.06 | 6.15 | 6.04 | |
Coefficient of variation for glucose (CV) (%) | 23.84 | 20.62 | 20.81 | 20.64 | 21.87 | 21.77 | |
Time in range (TIR) (%) | 96.28 | 97.67 | 97.58 | 98.24 | 96.39 | 97.72 | |
Time above range (TAR) (%) | 2 | 2 | 2 | 1 | 2 | 3 | |
Time below range (TBR) (%) | 2 | 1 | 0 | 0 | 1 | 0 | |
Mean area under the curve (AUC) > 180 mg/dL (%) | 1.78 | 1.72 | 1.82 | 1.63 | 3.28 | 1.90 | |
Mean area under the curve (AUC) < 70 mg/dL (%) | 1.94 | 0.61 | 0.61 | 0.13 | 0.33 | 0.38 | |
Mean area under the curve (AUC) < 54 mg/dL (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total daily dose of insulin (TDDI) (units) | 8.10 | 8.30 | 8.50 | 8.10 | 7.50 | 8.40 | |
Minimum daily dose of insulin (units) | 6.50 | 6.60 | 6.50 | 5.70 | 6.30 | 6.90 | |
Maximum daily dose of insulin (units) | 8.90 | 9.00 | 9.90 | 9.60 | 10.20 | 9.80 | |
Average demand for carbohydrates (grams) | 117.00 | 135.00 | 143.00 | 147.50 | 138.70 | 150.00 | |
Bolus size (daily) (units) | 3.10 | 3.60 | 4.60 | 4.80 | 4.60 | 5.50 | |
Automatic (daily) base (units) | 5.00 | 4.70 | 3.90 | 3.30 | 2.90 | 2.90 | |
Automatic (daily) correction (units) | - | - | 0.40 | 0.30 | 0.40 | 0.30 | |
Automatic mode (SmartGuard per week) (%) | - | 4 | 100 | 100 | 99 | 100 | |
Manual mode (per week) (%) | - | 96 | 0 | 0 | 1 | 0 | |
Days with insulin requirement < 8 units | 4 | 2 | 3 | 4 | 11 | 2 | |
Days of total daily dose of insulin < 8 units in February | Number | % | |||||
12.00 | 43.00 | ||||||
Days of total daily dose of insulin < 8 units in March | 10.00 | 32.00 | |||||
Days of total daily dose of insulin < 8 units in April (until 23 April) | 10.00 | 38.00 | |||||
Days throughout the follow-up when the total daily dose of insulin < 8 units | 25.33 | 37.67 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tekielak, A.; Seget, S.; Rusak, E.; Jarosz-Chobot, P. Can the AHCL System Be Used in T1D Patients with Borderline TDDI? A Case Report. Sensors 2021, 21, 7195. https://0-doi-org.brum.beds.ac.uk/10.3390/s21217195
Tekielak A, Seget S, Rusak E, Jarosz-Chobot P. Can the AHCL System Be Used in T1D Patients with Borderline TDDI? A Case Report. Sensors. 2021; 21(21):7195. https://0-doi-org.brum.beds.ac.uk/10.3390/s21217195
Chicago/Turabian StyleTekielak, Anna, Sebastian Seget, Ewa Rusak, and Przemysława Jarosz-Chobot. 2021. "Can the AHCL System Be Used in T1D Patients with Borderline TDDI? A Case Report" Sensors 21, no. 21: 7195. https://0-doi-org.brum.beds.ac.uk/10.3390/s21217195